Abcuro, Inc. is a biotechnology company focused on developing advanced immunotherapies to treat autoimmune diseases and cancer. The company operates in the biopharmaceutical market, specifically targeting dysfunctional immune pathways to create novel therapies. Abcuro takes a patient-centric approach, identifying and validating the role of these pathways in various diseases to discover new treatments. The company primarily serves patients suffering from autoimmune conditions and certain types of cancer. Abcuro's business model revolves around research and development, with revenue generated through partnerships, grants, and potential future sales of their proprietary therapies. The company is headquartered in Newton, MA, and is led by a team of experienced scientists and medical professionals. Key areas of focus include the role of KLRG1 T cells in diseases like Primary Biliary Cholangitis and Inclusion Body Myositis.

Keywords: immunotherapies, T cells, autoimmunity, cancer, biotechnology, patient-centric, immune pathways, biopharmaceutical, KLRG1, research and development.